The active participation of MAX IV in a number of international networks and the networking efforts of the facility staff to exchange knowledge with peers in their field from foreign institutions and develop jointly techniques and equipment resulted in a number of successful projects funded by European funding bodies.

These projects have the common goal of optimising services and guaranteeing that the tools and processes offered to the broad scientific community are constantly improved and developed further. This allows scientific breakthrough and preparedness to address Sustainable Development Goals. Moreover, the projects, in most cases, involve industrial partners that help bridging the fundamental knowledge with applications having market value, with the overall aim of achieving societal impact.

Please find below a list of European projects involving MAX IV.

The LEAPS-INNOV pilot project focuses on the implementation of new strategies and activities for long-term partnerships between industry and the European light sources, synchrotrons and free-electron lasers, with their tens of thousands of users.

LEAPS-INNOV aims at kick-starting the implementation of the LEAPS Technology Roadmap and, at the same time, at fostering a partnership with European industry through open innovation. It will offer joint technological developments and advanced research capabilities with LEAPS members for industry as collaborator, supplier and user.

The NFFA-Europe PILOT project is the extension to 2026 of NFFA-Europe, whose first five-year term ended on February 28, 2021. NFFA-Europe is a distributed research infrastructure that integrates nanofoundries (synthesis and manipulation of nanostructures) with fine analysis available at European large-scale facilities, creating a unique offer for the nanosciences and nanomaterials community.  The consortium involves twenty-two beneficiaries and also nine “third parties” as scientific service providers. The project, funded by the European Union with the Horizon 2020 call INFRAIA-03-2020: Pilot for a new model of Integrating Activities, is coordinated by Cnr-Iom. The beneficiaries include academic laboratories and SMEs from nine Member States of the European Union (France, Germany, Greece, Italy, Portugal, Slovenia, Spain, Sweden and Austria) and from Switzerland, while there are three international organizations. Third parties also introduce new specialized services in the offer of Transnational Access.

iNEXT-Discovery aims to enable access to structural biology research infrastructures for all European researchers, and especially also for non-experts in structural biology. For that reason it brings together a diversity of large research facilities and other groups in a single consortium. Funded by the European Commission Horizon-2020 framework program from February 2020 for a period of four years, iNEXT-Discovery is built on three pillars:

  • Allowing trans-national access for external researchers, following rapid peer-review on scientific excellence and translational research potential.
  • Performing networking and training activities, such as practical courses and workshops, to enlarge and strengthen the structural biology community.
  • Undertaking joint research activities, to increase the quality and quantity of the access offered by our facilities.

ExPaNDS is the European Open Science Cloud (EOSC) Photon and Neutron Data Service.

The ambitious ExPaNDS project is a collaboration between 10 national Photon and Neutron Research Infrastructures (PaN RIs) as well as EGI. The project aims to deliver standardised, interoperable, and integrated data sources and data analysis services for Photon and Neutron facilities.


Hanseatic League of Science (HALOS) is an EU project in the program area Öresund-Kattegatt-Skagerak (ÖKS) interreg that started 1st of February 2019. HALOS will build a unique collaboration between Hamburg and South-West Scandinavia, bring together the four unique research facilities MAX IV, ESS, DESY and European XFEL, and create a centre for integrated, world-leading Life Science innovation and research.

The overarching goal of MUMMERING is to create a research tool that encompasses the wealth of new 3D imaging mo-dalities that are surging forward for applications in materials engineering, and to create a doctoral programme that trains 15 early stage researchers (ESRs) in this tool. This is urgently needed to prevent that massive amounts of valuable tomogra-phy data ends on a virtual scrapheap. The challenge of handling and analysing terabytes of 3D data is already limiting the level of scientific insight that is extracted from many data sets. With faster acquisition times and multidimensional modali-ties, these challenges will soon scale to the petabyte regime. To meet this challenge, we will create an open access, open source platform that transparently and efficiently handles the complete workflow from data acquisition, over reconstruction and segmentation to physical modelling, including temporal models, i.e. 3D “movies”. We consider it essential to reach this final step without compromising scientific standards if 3D imaging is to become a pervasive research tool in the visions for Industry 4.0.

The aim of the CALIPSOplus project was to remove barriers for access to world-class accelerator-based light sources in Europe and in the Middle East. To this end, more than 179,000 hours of trans-national access have been provided to these research infrastructures and specific programmes were installed to teach new users how to successfully use synchrotrons and FELs. Dissemination activities targeting industry were complemented by tailor-made support and access programmes for this user group. In parallel the consortium was collaborating on constantly developing technology to keep the facilities at the cutting-edge.

Scientists in the field of structural and computational biology, biophysics, protein formulation and stability have formed the consortium “Protein-excipient Interactions and Protein-Protein Interactions in formulation”, PIPPI, funded under the European Horizon2020 programme. The overall goal is to develop a public database with cutting-edge knowledge about the properties of proteins in pharmaceutical formulations.


PIPPI will combine systematic investigations of the physicochemical behavior of a number of proteins with an in-depth understanding of the molecular interactions behind the macroscopic behavior. The consortium consists of both academic and industrial partners located in Denmark, Sweden, Germany and United Kingdom.

Page manager: Doriana Orbanic August 8, 2022